Partner Content Partner Content The HNSCC immunotherapy race is on - and it's going to be cl... While improper to compare life saving treatments to buses - the metaphor when it comes to head and neck squamous cell carcinoma (HNSCC) is clear.
R&D T-cell specialist Immunocore raises $320m in private finance Immunocore, a UK-based biotech specialising in T-cell receptor drugs has raised $320 million (£205 million), making it Europe's largest private life sciences financing.
Cancer Lilly and Immunocore collaborate on novel cancer therapies Eli Lilly and Immunocore have agreed to collaborate on R&D into novel T-cell-based cancer therapies.
News Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
